^
    1year
    A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) (clinicaltrials.gov)
    P1/2, N=10, Terminated, Astellas Pharma Global Development, Inc. | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M negative
    |
    erlotinib • Xospata (gilteritinib)
    1year
    SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P2/3, N=14, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR mutation • EGFR T790M negative
    |
    Tagrisso (osimertinib) • izalontamab (SI-B001)
    1year
    Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study. (PubMed, Lung Cancer)
    Selected population could obtain clinical benefit from afatinib plus bevacizumab, based on rebiopsy results after osimertinib resistance.
    P2 data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR T790M • EGFR C797S • EGFR positive • EGFR T790M negative
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Gilotrif (afatinib)
    1year
    NCI-2021-04325: Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    1year
    Predicting the T790M mutation in non-small cell lung cancer (NSCLC) using brain metastasis MR radiomics: a study with an imbalanced dataset. (PubMed, Discov Oncol)
    Our study demonstrates that, even when dealing with an imbalanced EGFR T790M dataset, reasonable predictive outcomes can be achieved by employing an appropriate combination of resampling techniques and classifiers. This approach has significant potential for enhancing T790M mutation detection in NSCLC patients with brain metastasis.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR positive • EGFR T790M negative
    over1year
    Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure. (PubMed, Oncol Lett)
    PD-1 inhibitor combined with chemotherapy and bevacizumab did not show a clear advantage over PD-1 inhibitor combined with chemotherapy alone (mPFS, 6.2 vs. 4.4 months; P=0.681), although it resulted in an improved overall response rate (ORR) and disease control rate...Therefore, it is suggested that PD-1 inhibitor-based combinations should be a priority treatment option in selective populations, such as those with low ECOG-PS scores, T790M-negative status or high PD-L1 expression in EGFR-mutant NSCLC after TKI failure. The use of immunotherapy and chemotherapy in combination with antiangiogenic agents appears to be a promising combination therapy for such patients.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR T790M • EGFR expression • EGFR positive • EGFR T790M negative
    |
    Avastin (bevacizumab)
    over1year
    MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=69, Recruiting, Emory University | Phase classification: P1b --> P1 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR mutation • EGFR T790M negative
    |
    Tagrisso (osimertinib) • MRX2843
    over1year
    Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing. (PubMed, Expert Rev Anticancer Ther)
    This study indicates that ddPCR may contribute as a supplement to NGS in liquid biopsies for T790M detection in EGFR-TKIs relapsed patients and help to optimize the treatment strategies, especially for those without coexistence of EGFR-sensitive mutation. www.clinicaltrials.gov identifier is NCT05458726.
    Journal • Next-generation sequencing • Polymerase Chain Reaction • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR T790M negative
    over1year
    A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=86, Terminated, Jiangsu Simcere Pharmaceutical Co., Ltd. | Trial completion date: Dec 2023 --> Jul 2023 | Recruiting --> Terminated; The study was terminated due to the sponsor's research and development strategy adjustment.
    Trial completion date • Trial termination • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK positive • ROS1 positive • EGFR T790M negative
    |
    docetaxel • irinotecan • leucovorin calcium • Enweida (envafolimab) • suvemcitug (APX003)
    almost2years
    EATON: EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations (clinicaltrials.gov)
    P1, N=18, Completed, University of Cologne | Recruiting --> Completed | Trial completion date: Apr 2023 --> Nov 2023
    Trial completion • Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M negative
    |
    Mekinist (trametinib) • Tagrisso (osimertinib) • nazartinib (EGF816)
    almost2years
    Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study (clinicaltrials.gov)
    P1/2, N=43, Active, not recruiting, MedImmune LLC | Phase classification: P1b/2 --> P1/2 | Trial completion date: Sep 2024 --> Jan 2025
    Phase classification • Trial completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR T790M negative
    |
    Tagrisso (osimertinib) • oleclumab (MEDI9447) • imaradenant (AZD4635)
    almost2years
    BLOSSOM: Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov)
    P2, N=73, Completed, Samsung Medical Center | Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023
    Trial completion • Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M negative
    |
    Tagrisso (osimertinib)